paclitaxel · Bristol-Myers · NDA 021660
Abraxane
Earliest generic entry, as listed
12 Jul 2034
Blocked by patent: US 9511046.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9511046 | — | 12 Jul 2034 |
| US 9511046 | use U-1434 | 12 Jan 2034 |
| US 9393318 | — | 4 Sep 2032 |
| US 9597409 | — | 4 Sep 2032 |
| US 9393318 | use U-1290 | 4 Mar 2032 |
| US 9597409 | use U-1290 | 4 Mar 2032 |
| US 8034375 | — | 13 Feb 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021660 · 001 · RLD | powder, intravenous | 100MG/VIAL | 12 Jul 2034 |
Expired or delisted (7)
- US 7758891 · — · 21 Aug 2026
- US 8268348 · — · 21 Aug 2026
- US 9101543 · — · 21 Aug 2026
- US 8034375 · use U-1290 · 13 Aug 2026
- US 7758891 · use U-1434 · 21 Feb 2026
- US 8268348 · use U-1290 · 21 Feb 2026
- US 9101543 · use U-1434 · 21 Feb 2026